BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.14% | -16.41% | 12.67% | 49.32% | 74.27% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.26% | 20.47% | -21.58% | -55.09% | -85.00% |
| Change in Net Operating Assets | 83.46% | -64.16% | -100.61% | -97.30% | -30.08% |
| Cash from Operations | -244.71% | -394.40% | -267.37% | -74.94% | 33.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.30% | 4.53% | -- | -- | -- |
| Cash from Investing | 103.30% | 4.53% | -- | -- | -- |
| Total Debt Issued | -200.00% | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -- | -- | -- |
| Issuance of Common Stock | 4.86% | 93.61% | 86.50% | 244.63% | 89.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.33% | 89.48% | 80.75% | 239.20% | 90.60% |
| Foreign Exchange rate Adjustments | 63.64% | 185.00% | -26.67% | 170.83% | 106.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196.64% | -208.60% | -189.83% | 251.20% | 1,414.49% |